Zobrazeno 1 - 10
of 57
pro vyhledávání: '"A. C. Martinsen"'
Autor:
T. Johansen, M. Matre, M. Løvstad, A. Lund, A. C. Martinsen, A. Olsen, F. Becker, C. Brunborg, J. Ponsford, J. Spikman, D. Neumann, S. Tornås
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background Acquired brain injury (ABI) often leads to persisting somatic, cognitive, and social impairments. Cognitive impairments of processing speed, sustained attention, and working memory are frequently reported and may negatively affect
Externí odkaz:
https://doaj.org/article/656820a550a644d8aba15d4729af706e
Autor:
Marian S. Solbak, Mette K. Henning, Andrew England, Anne C. Martinsen, Trond M. Aaløkken, Safora Johansen
Publikováno v:
European Radiology Experimental, Vol 4, Iss 1, Pp 1-8 (2020)
Abstract Background We investigated the impact of varying contrast medium (CM) densities and x-ray tube potentials on contrast enhancement (CE), image quality and radiation dose in thoracic computed tomography (CT) using two different scanning techni
Externí odkaz:
https://doaj.org/article/8d41182ff90f4a0e8653fc784fde316c
Publikováno v:
The Journal of Hospital Infection
Journal of Hospital Infection
Journal of Hospital Infection
Insufficiently protected healthcare workers (HCWs), defined as high-risk contacts of patients with coronavirus disease 2019 (COVID-19), are routinely quarantined. This study evaluated the transmission of infection from a symptomatic patient with COVI
Autor:
Arne K. Sandvik, Maya Olaisen, Elin Synnøve Røyset, Reidar Fossmark, Arnar Flatberg, Atle van Beelen Granlund, Tom C. Martinsen
Publikováno v:
Inflammatory Bowel Diseases
Background Microbiota is most likely essential in the pathogenesis of Crohn’s disease (CD). Fecal diversion after ileocecal resection (ICR) protects against CD recurrence, whereas infusion of fecal content triggers inflammation. After ICR, the majo
Autor:
Tom C. Martinsen, Helge L. Waldum
Publikováno v:
Therapeutic Advances in Gastroenterology
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Therapeutic Advances in Gastroenterology
Therapeutic Advances in Gastroenterology
Background: Oral 5-aminosalicylic acid (5-ASA) is the mainstay treatment of ulcerative colitis (UC) and therapy with oral 5-ASA is associated with beneficial outcomes. We have examined factors associated with the persistence of oral 5-ASA treatment i
Autor:
Grethe Albrektsen, Maya Olaisen, Bodil Gilde, Atle van Beelen Granlund, Elin Synnøve Røyset, Arne K. Sandvik, Arnar Flatberg, Olav Spigset, Reidar Fossmark, Wenche Rødseth Brede, Tom C. Martinsen
Publikováno v:
Alimentary Pharmacology & Therapeutics
Alimentary Pharmacology and Therapeutics
Alimentary Pharmacology and Therapeutics
Background 5‐aminosalicylic acid (5‐ASA) is the first‐line therapy for ulcerative colitis (UC). 5‐ASA acts locally in the colonic mucosa by numerous proposed mechanisms, and is metabolised by N‐acetyltransferase (NAT). Large variations in m
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 3 (2010)
Externí odkaz:
https://doaj.org/article/17cb18e3cb9440aeab6a9e0124eb2812
Publikováno v:
Journal of Crohn's and Colitis. 14:S605-S606
Background Oral mesalazine is the mainstay treatment of ulcerative colitis (UC). Mesalazine exerts its anti-inflammatory effect locally in the colonic mucosa. The mucosal mesalazine concentration is inversely correlated with the degree of inflammatio
Publikováno v:
International Journal of Molecular Sciences
20:6031
20:6031
Gastric juice is a unique combination of hydrochloric acid (HCl), lipase, and pepsin. Acidic gastric juice is found in all vertebrates, and its main function is to inactivate microorganisms. The phylogenetic preservation of this energy-consuming and,